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Abstract
Adipose tissue is a critical mediator in obesity-induced insulin resistance. Previously we have demonstrated that
pharmacological lowering of glycosphingolipids and subsequently GM3 by using the iminosugar AMP-DNM, strikingly
improves glycemic control. Here we studied the effects of AMP-DNM on adipose tissue function and inflammation in detail
to provide an explanation for the observed improved glucose homeostasis. Leptin-deficient obese (Lep
Ob) mice were fed
AMP-DNM and its effects on insulin signalling, adipogenesis and inflammation were monitored in fat tissue. We show that
reduction of glycosphingolipid biosynthesis in adipose tissue of Lep
Ob mice restores insulin signalling in isolated ex vivo
insulin-stimulated adipocytes. We observed improved adipogenesis as the number of larger adipocytes was reduced and
expression of genes like peroxisome proliferator-activated receptor (PPAR) c, insulin responsive glucose transporter (GLUT)-
4 and adipsin increased. In addition, we found that adiponectin gene expression and protein were increased by AMP-DNM.
As a consequence of this improved function of fat tissue we observed less inflammation, which was characterized by
reduced numbers of adipose tissue macrophages (crown-like structures) and reduced levels of the macrophage chemo
attractants monocyte-chemoattractant protein-1 (Mcp-1/Ccl2) and osteopontin (OPN). In conclusion, pharmacological
lowering of glycosphingolipids by inhibition of glucosylceramide biosynthesis improves adipocyte function and as a
consequence reduces inflammation in adipose tissue of obese animals.
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Introduction
Adipose tissue essentially contributes to the obesity-driven
insulin resistance syndrome as it can buffer excess of energy and
secretes adipokines, which control metabolic homeostasis. How-
ever, it is not exactly understood how obesity causes this insulin
resistance. Some extreme obese individuals are still able to handle
increased glucose loads, whereas mildly obese individuals show
severe insulin resistance and type 2 diabetes. This suggests that not
the absolute amount of adipose tissue per se determines the
development of insulin resistance, but that alternative explanations
are possible. As long as adipose tissue can expand, in other words
can store excess free fatty acids (FFA), this prevents occurrence of
insulin resistance [1–6].
Two nonexclusive mechanisms have been proposed, which may
explain how adiposity contributes to insulin resistance. It has been
suggested that an increase in adiposity causes a state of low grade
chronic inflammation. Endothelial cells, adipocytes and recruited
inflammatory adipose tissue macrophages (ATM) all contribute to
the pro-inflammatory environment in adipose tissue of obese
individuals. The presence of this ensemble is thought to promote
insulin resistance [7–14]. The initiation of the inflammatory
response is incompletely understood, but is in part attributed to
adipocytes. It is thought that at the onset of the inflammatory
response adipocytes undergo necrotic-like death. This results in
local autonomous inflammation, and the presence of ATM,
forming so-called crown-like structures [15]. The recruited
inflammatory macrophages produce additional chemokines and
cytokines, resulting in worsening of inflammation and subsequent
insulin resistance. For example, monocyte-chemo attractant
protein-1 (Mcp-1, also referred to as Chemokine (C-C motif)
ligand 2, Ccl-2) and its receptor, chemokine-receptor-2 (Ccr-2),
have both been reported to modulate infiltration of macrophages
into adipose tissue, thereby contributing to insulin resistance [16–
18]. In addition, it has been demonstrated that osteopontin (OPN)
is increased in adipose tissue of mice receiving a high fat diet.
ATM are the main producers of OPN during development of diet-
induced obesity. OPN has been shown to amplify Ccl-2 mediated
migration of macrophages [19]. Mice lacking a functional OPN
gene, despite being obese, are insulin sensitive. Their adipose
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4723tissue shows decreased macrophage infiltration and reduced
inflammation.
Alternatively, increased lipotoxicity may cause insulin resis-
tance. If the amount of fuel that enters tissue cannot be dealt with,
either from the oxidation, or storage, point of view, metabolites are
generated which interfere with insulin action, either directly or
indirectly [4,20,21]. Lipid metabolites, for instance ceramide
species, are of particular interest here. Obesity is characterized by
increased levels of FFA. Importantly, FFA have been reported to
trigger pro-inflammatory responses in macrophages by acting on
toll like receptors [22–24], and thus could act as intermediates in
the vicious cycle promoting insulin resistance and inflammation.
The mechanism(s) by which FFA are causing these effects are still
largely unknown. FFA, such as palmitate, are essential building
blocks of glycosphingolipids (GSL) [25,26]. Several lines of
evidence, obtained both in vitro and in vivo, point to a crucial role
of GSL in the development of insulin resistance. Ceramide is
reported to contribute to impaired insulin signalling [27]. More
recently, glycosphingolipids like the ganglioside GM3 have also
been shown to inhibit insulin signalling [28–32]. Of interest, the
concentration of GM3 in cultured adipocytes is markedly
increased by the pro-inflammatory cytokine TNF-a [29]. It has
been demonstrated by us that inhibition of glucosylceramide
synthase (GCS) activity with N-(5-adamantane-1-yl-methoxy)-
pentyl-1-deoxynojirimycin (AMP-DNM) corrects insulin resistance
in cultured adipocytes from obese individuals and 3T3 cells
exposed to TNF-a [33].
The importance of glycosphingolipids in obesity-induced insulin
resistance has recently been further illustrated by pharmacological
interventions in animal models [33,34]. We observed that
inhibition of glucosylceramide synthase (GCS) activity in several
rodent models of obesity reverses the insulin resistance syndrome.
Feeding rodents with AMP-DNM lowered circulating glucose and
HbA1c levels, improved oral glucose tolerance, improved insulin
sensitivity in muscle and liver and resulted in b cell preservation
[33]. In addition, inhibition of GCS using (1R,2R)-nonanoic
acid[2-(2,3-dihydro-benzo [1,4] dioxin-6-yl)-2-hydroxy-1-pyrroli-
din-1-ylmethyl-ethyl]-amide-L-tartaric acid salt (Genz-123346)
showed comparable improved glycemic control and insulin
resensitizing effects [34]. It has very recently also been reported
that reduction of ceramide synthesis by inhibition of serine-
palmitoyl transferase using myriocin, or via the inactivation of the
dihydroceramide desaturase-1 gene, reduces insulin resistance in
rodents, either evoked by glucocorticoids or saturated free fatty
acids, or in obese animals [35].
Given the dramatic beneficial responses in glycemic control of
obese animals following exposure to the iminosugar AMP-DNM,
we investigated whether inhibiting GCS, next to a direct beneficial
effect on adipocytes, also consequently was reflected by reduced
inflammation in adipose tissue of leptin-deficient obese (Lep
Ob)
mice.
Results
The glucosylceramide synthesis inhibitor AMP-DNM
normalizes glucose homeostasis in Lep
Ob mice
In the present study leptin-deficient obese Lep
Ob mice were
exposed to 100 mg AMP-DNM /kg bodyweight/day for 4 weeks.
The inhibitor was well tolerated and caused no overt side effects. A
minor reduction (p=0.0048) in the percentage of body weight
gain was noted (166615 in the Lep
Ob treated with AMP-DNM
versus 202611 in Lep
Ob). Glucosylceramide, but not ceramide,
was reduced in plasma from inhibitor treated animals (see table 1).
Both glucose homeostasis and insulin signalling were markedly
improved. Treated Lep
Ob mice showed (near) normal HbA1c, non-
fasted blood glucose concentrations and glucose clearance upon
oral challenge in an oral glucose tolerance test (OGTT). Fasted
insulin levels and the homeostatic model assessment (HOMA)
index, which is clearly increased in Lep
Ob animals, were
significantly reduced upon treatment.
AMP-DNM improves adipocyte function in Lep
Ob mice
First, the effect of AMP-DNM treatment of Lep
Ob animals on
adipocyte function was investigated. For this purpose, tissue slides
stained with haematoxylin and eosin were examined. Adipocytes
appeared larger in Lep
Ob mice when compared to those in lean
mice (Fig. 1B versus 1A). When analyzing the average EWAT
adipocyte size, calculated per animal, we observed a significant
difference (p,0.0001) between lean mice (29236455 mm
2) and
Lep
Ob mice (79926494 mm
2). We however did not observe a
significant difference between Lep
Ob animals and AMP-DNM
treated animals (Fig. 1A–C). Interestingly, when studying
individual adipocytes we observed a change in distribution of size
(Fig. 1D). As expected the adipocytes in lean mice (black curve)
were predominantly smaller than adipocytes in Lep
Ob mice (red
curve). Following treatment with AMP-DNM a reduction of the
median adipocyte size was observed in Lep
Ob mice (green curve),
mainly due to a shift to the left of the 2
nd and 3
th quartiles of the
distribution, reflecting reduced numbers of the large adipocytes.
Adipocyte size did not normalize to sizes observed in lean mice.
The distribution frequencies were analysed in detail by using a non
parametric 2-tailed Kolmogorov-Smirnov Z test. The distributions
are significantly different (lean versus Lep
Ob p#0.0005; Lep
Ob
versus Lep
Ob+AMP-DNM p=0.002). We also studied adipocytes
Table 1. Summary of the effects of AMP-DNM on glycosphingolipid content and blood glucose homeostasis.
Lean Lep
Ob Lep
Ob AMP-DNM Lean versus Lep
Ob
Lep
Ob versus Lep
Ob
AMP-DNM
Glucosylceramide (nmol/ml) 6.2060.58 12.9362.08 3.6860.99 P=0.0001 P=0.0022
Ceramide (nmol/ml) 6.7761.38 15.4762.93 12.9563.02 P=0.0003 n.s.
HbA1C (%) 4.9260.71 9.6461.22 5.0861.06 P,0.0001 P=0.0006
Blood glucose (millimolar) 10,0260.45 16.3063.95 11.5861.55 P=0.0077 P=0.0159
Insulin (ng/ml) 0.7260.27 19.91615.44 4.5160.67 P=0.024 P=0.032
HOMA index 6.3862.45 259.46173.8 49.71625.18 P=0.001 P=0.0077
OGTT (Area under the curve) 12366114.2 22666202.3 1580633.58 P,0.0001 P=0.0003
Data are means6S. E. M. Actual P values are indicated and n.s. means no significant difference (n=5 animals per group).
doi:10.1371/journal.pone.0004723.t001
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sizes appeared smaller in the OAT depot when compared to the
EWAT depot. Weobserved a comparable shift to theleftwith AMP-
DNM and the distributions again appeared significantly different
using the Kolmogorov-Smirnov Z test (lean versus Lep
Ob p#0.0005;
Lep
Ob versus Lep
Ob+AMP-DNM p,0.0005) (data not shown). The
amount of EWAT in Lep
Ob animals (both pads 39206175.1 mg)
tended to be lower upon AMP-DNM treatment (both pads
3366655 mg), but the reduction failed to reach significance
(p=0.10) (Fig. 1E). No significant reduction in EWAT weight was
observed when normalized for body weight.
In adipose tissue we observed a significant reduction of GM3
(4.5560.32 pmol/mg versus 1.9360.57 pmol/mg), again without
affecting ceramide (52.4268.61 pmol/mg versus 62.97624.2 pmol/
mg) (Fig. 2A). We next studied insulin signalling in adipocytes, which
were isolated from EWAT of Lep
Ob mice, or Lep
Ob mice exposed to
AMP-DNM. When adipocytes were stimulated ex-vivo with insulin
for 10 min no phosphorylation of Akt/PKB was observed in Lep
Ob
derived adipocytes, whereas in the case of cells from treated animals
clear phosphorylation of Akt/PKB was detected (Fig. 2B).
The expression of several key genes involved in adipogenesis
was analyzed. Comparing Lep
Ob EWAT with comparable lean
tissue, a 3-fold decrease in expression of peroxisome proliferator-
activated receptor (PPAR)c, an 80-fold decrease in expression of
the adipocyte-specific serine protease adipsin and a 4-fold decrease
in expression of the insulin responsive glucose transporter GLUT4
was detected using real-time PCR (Fig. 2 C–E). Decreased
expression of these genes is in line with the reported loss of
adipocyte differentiation and function in Lep
Ob mice [36–42].
Interestingly, all these markers showed a significant increase when
compared to untreated Lep
Ob mice upon inhibition of glucosylcer-
amide synthesis; Pparc (2-fold), adipsin (6-fold) and GLUT-4 (3-
fold), suggesting that adipogenesis is normalizing. A comparable
pattern was also observed for CCAAT/enhancer binding protein
(C/EBP)a and adipocyte fatty-acid-binding protein, aP2/(FABP4).
On the other hand adipogenesis inhibiting Pref1 was undetectable
in lean and AMP-DNM treated animals, but was detected in
Lep
Ob mice (data not shown). Importantly, we also observed that
expression of the adipokine adiponectin/Acrp30 increased in the
presence of AMP-DNM. Adiponectin RNA was 5-fold decreased
in Lep
Ob mice compared to normal, and increased by 3-fold in
adipose tissue of AMP-DNM treated obese mice (Fig. 3A).
Adiponectin protein levels in adipose tissue lysates and in serum
were determined. In adipose tissue a 2-fold decrease was observed
in Lep
Ob mice when compared to lean mice. AMP-DNM
treatment significantly increased (1.3-fold) adiponectin in adipose
tissue (Fig. 3B). Serum adiponectin levels were 1.4-fold decreased
in Lep
Ob mice compared to lean control mice. Adiponectin showed
Figure 1. Adipose tissue analysis after lowering of glycosphingolipid content. Haematoxylin and eosin staining of adipose tissue of (A) lean
mice, (B) LepOb mice and (C) LepOb mice following reduction of glycosphingolipid content. (D) Analysis of adipocyte cell size distribution in lean
mice (black line), in LepOb mice (red line) and in AMP-DNM treated LepOb mice (green line). (E) EWAT weight. Data are depicted on the Y-axis as
mean6S.E.M. (n=5 per group). Actual p values are depicted in the graphs. Bars in the photographs represent 100 mm. The arrows in panel B indicate
crown-like structures. For the distribution of adipocyte size at least 150 cells were analysed per animal (for details see methods).
doi:10.1371/journal.pone.0004723.g001
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PLoS ONE | www.plosone.org 3 March 2009 | Volume 4 | Issue 3 | e4723Figure 2. Restoration of insulin signalling and normalization of adipogenesis, following lowering of adipose tissue
glycosphingolipid content (A) Reduction of GM3 concentration (open bars, left Y-axis), but not ceramide (hatched bars, right Y-axis), in adipose
tissue by AMP-DNM (B) Restoration of insulin signalling by insulin as demonstrated by western blot analysis of AKT phosphorylation. Adipogenesis is
improved as is demonstrated by real time PCR analysis of (C) Pparc (D) adipsin and (E) GLUT4. In the graphs values are depicted as mean6S.E.M. (n=5
per group), with p values indicated in the graphs.
doi:10.1371/journal.pone.0004723.g002
Figure 3. Inhibition of glycosphingolipid synthesis increases adiponectin expression. Correction of the adipokine adiponectin/Acrp30 as
demonstrated by (A) real time PCR and analysis of protein levels in (B) adipose tissue and (C) plasma by ELISA. (D) Westernblot analysis of adiponectin
protein in plasma. In the graphs values are depicted as mean 6 S.E.M. (n=5 per group), with p values indicated in the graphs. The arrows in panel D
refer to middle molecular weight species of adiponectin.
doi:10.1371/journal.pone.0004723.g003
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reach significance (p=0.10) (Fig. 3C). By western blot analysis we
observed that several middle molecular weight species of
adiponectin were lower in Lep
Ob mice when compared to
lean mice. Following treatment with AMP-DNM this almost
normalized to levels observed in lean mice (Fig. 3D).
In conclusion, inhibition of synthesis of glucosylceramide and
glycosphingolipids directly beneficially affects features of adipo-
cytes in adipose tissue of Lep
Ob mice, including insulin sensitivity
and adipogenesis.
AMP-DNM reduces macrophages in adipose tissue
As we clearly observed improved adipocyte function, we next
investigated whether AMP-DNM treatment consequently also
reduced the inflammatory status of adipose tissue in Lep
Ob mice.
Recently it has been demonstrated that non-viable adipocytes in
leptin receptor-deficient mice and obese human subjects lack
perilipin protein [15,43]. Using immunohistochemistry double
staining, we confirmed this also in Lep
Ob mice. The crown-like
structures showed F4/80 positive adipose tissue macrophages
(ATM) surrounding an adipocyte, which lost perilipin positive
signal (Fig. 4A). As expected, we observed F4/80
+ crown-like
structures, i.e. ATM surrounding dead adipocytes, in tissue
specimens of obese animals (Fig. 1B, Fig. 4B indicated with
arrows). In tissue specimens of lean animals these structures could
not be detected and they were hardly detectable in Lep
Ob mice
treated with the iminosugar AMP-DNM (Fig. 1A, C and Fig. 4C).
Next, we analyzed the number of F4/80 positive crown-like
structures in Lep
Ob animals and in AMP-DNM fed Lep
Ob animals.
Representative images are depicted in Fig. 4B and C (indicated by
arrows is the F4/80 staining, Fig. 4B). A graph summarizing the
quantitative analysis of crown-like structures is depicted in Fig. 4D.
Real time PCR showed a consistent reduction in F4/80 mRNA in
the AMP-DNM fed Lep
Ob mice. F4/80 mRNA was approximately
4-fold increased in Lep
Ob adipose tissue and normalized in treated
Lep
Ob mice (Fig. 4E). Furthermore, CD11c gene expression, which
Figure 4. Reduced macrophage content in adipose tissue after inhibition of glycosphingolipid content with the iminosugar AMP-
DNM. (A) Immunohistochemical analysis of crown-like structures in LepOb mice using double staining for F4/80 (red) and perilipin (blue). F4/80
staining in (B) LepOb and (C)AMP-DNM fed LepOb mice. (D) Quantification of crown-like structures in lean, LepOb and AMP-DNM treated LepOb
mice. (E) Real time PCR analysis of F4/80 expression and (F) CD11c expression in lean, LepOb and LepOb mice fed AMP-DNM. Data are depicted on
the Y-axis as mean6S.E.M. (n=5 per group). Actual p values are depicted in the graphs. Bars in the photographs represent 100 mm.
doi:10.1371/journal.pone.0004723.g004
Table 2. Inflammatory mediators induced in Lep
Ob mice and
reverted by AMP-DNM.
Lep
Ob versus lean control Lep
Ob AMP-DNM versus Lep
Ob
Symbol P value Fold up/down Symbol P value Fold down/up
Spp1/OPN 0,014 20,2 Spp1 0,012 22,5
Ccl2 0,000008 9,1 Ccl2 0,0017 22,4
Il10 0,00017 6,9 Il10 0,0054 21,9
Il3 0,0118 5,8 Il3 0,074 23,6
Ccl7 0,000024 5,2 Ccl7 0,046 21,8
Ccl12 0,000043 4,2 Ccl12 0,062 21,6
Ccl9 0,000083 3,0 Ccl9 0,0069 21,9
Ccr5 0,0010 2,4 Ccr5 0,0047 21,8
Itgam 0,0022 1,8 Itgam 0,039 21,5
Tnfrsf1b 0,0031 1,6 Tnfrsf1b 0,022 21,3
Ccr4 0,010 23,0 Ccr4 0,030 1,7
Ccl24 0,000004 23,7 Ccl24 0,056 1,6
Cxcl11 0,000043 29,7 Cxcl11 0,013 3,1
Data depicted are average up -or down regulated inflammatory genes when
Lep
Ob mice are compared to lean control mice (left three columns), which are
reverted by treatment with AMP-DNM (right three columns). Actual P values are
indicated, in italics P values showing a trend, not reaching significance.
doi:10.1371/journal.pone.0004723.t002
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following treatment with AMP-DNM (Fig. 4F) [24,44].
These findings indicate that AMP-DNM treatment results in
less crown-like structures and near normalisation of ATM
numbers in EWAT of Lep
Ob mice.
Anti-inflammatory effect of AMP-DNM
Next, we studied inflammation in adipose tissue in more detail
by analysing gene expression profiles in EWAT from lean C57BL/
6J control mice, Lep
Ob mice and Lep
Ob mice treated with AMP-
DNM. Q-PCR arrays were used, focussing on inflammatory
cytokines and receptors (analyzed genes are listed in Supplemen-
tary data table S1). The most regulated genes are shown in table 2.
AMP-DNM treatment of Lep
Ob mice most pronouncedly effected
expression of osteopontin/OPN (on average 20-fold increased in
Lep
Ob and 2.5-fold reduced upon treatment) and Ccl2 (on average
9-fold increased in Lep
Ob and 2.5- fold reduced upon treatment
(Fig. 5A, C). As measured by ELISA, Ccl2 in serum of Lep
Ob mice
was also found to be lower upon treatment (Fig. 5B). OPN in
serum of Lep
Ob mice was hardly increased, but reduced by AMP-
DNM treatment (Fig. 5D). The mRNA encoding the chemokine
Cxcl11 was on average 10-fold reduced in adipose tissue of Lep
Ob
mice. In treated animals its concentration was 3-fold increased (see
table 2). Table 3 shows the genes of which expression did increase
in Lep
Ob mice, but was not affected by AMP-DNM. Ccl-8 is the
most striking in this respect (on average 12-fold increased in obese
animals but not changed by inhibitor treatment). Furthermore, we
observed that expression of TNFa increased in Lep
Ob adipose
tissue, but AMP-DNM treatment did not correct this. Table 4
shows the genes of which expression was not changed in Lep
Ob,
but is affected by AMP-DNM treatment. For none of the genes
upregulated by AMP-DNM, a clear anti-inflammatory action is
documented.
In conclusion, two important proteins involved in the
recruitment of ATM to adipose tissue and local inflammation,
Ccl2 and OPN, were down-regulated in adipose tissue after
treatment with AMP-DNM.
Discussion
The present study reveals for the first time that partial inhibition
of glucosylceramide biosynthesis, and subsequent glycosphingo-
lipids, not only restores insulin sensitivity of adipocytes in Lep
Ob
mice, but also improves adipocyte function and consequently
reduces the number of macrophages (crown-like structures) and
local inflammation.
EWAT weight showed a trend towards reduction in AMP-
DNM fed Lep
Ob mice. Possibly, prolonged exposure to AMP-
DNM could result in a more significant reduction. Importantly,
the unresponsiveness of the insulin receptor towards insulin was
found to be reversed in adipocytes isolated from adipose tissue of
AMP-DNM treated Lep
Ob mice. Other relevant changes in the
adipose tissue were also improved by AMP-DNM treatment.
Several genes whose expression is reduced in adipose tissue of
obese Lep
Ob mice, such as PPARc, adipsin, GLUT4, C/EBPa and
aP2/FABP4 showed an increase following AMP-DNM treatment.
Pref-1, which negatively regulates adipogenesis, was not detected
in lean, or AMP-DNM treated Lep
Ob mice. Detailed analysis of
adipocyte size revealed that AMP-DNM treatment reduced
adipocyte size, both in EWAT and OAT. These findings suggest
Figure 5. The chemo attractants Ccl2 and OPN are reduced in adipose tissue and in the circulation following treatment with AMP-
DNM. (A) Real time PCR analysis of Ccl2 expression in adipose tissue (B) Analysis of Ccl2 protein by ELISA in plasma (C) Real time PCR analysis of OPN
expression in adipose tissue (D) Analysis of OPN protein by ELISA in plasma. Data are depicted on the Y-axis as mean6S.E.M. (n=5 per group). Actual
p values are depicted in the graphs.
doi:10.1371/journal.pone.0004723.g005
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also found an increase in expression of the adipokine adiponectin
at the level of RNA and protein in adipose tissue. In plasma
adiponectin levels tended to increase as well and western blot
analysis revealed an increase of intermediate molecular weight
forms of adiponectin in the presence of AMP-DNM. Adiponectin
has been shown to improve whole body insulin sensitivity and
shows anti-inflammatory properties. In vitro, monocyte adherence
to endothelial cells is reduced by adiponectin as endothelial cell
adhesion molecules such as intercellular adhesion molecule-1 and
vascular cell adhesion molecule-1 are suppressed. In addition, pro-
inflammatory mediators such as Ccl2 are suppressed in macro-
phages by adiponectin [36,37,45,46]. Recently, it was reported
that modest over expression of circulating adiponectin in Lep
Ob
mice completely rescued the diabetic phenotype in Lep
Ob mice. In
addition, increased expression of PPARc target genes and reduced
ATM infiltration in adipose tissue and systemic inflammation was
observed. These mice however were morbidly obese, with more
adipose tissue than their Lep
Ob littermates [5]. The effects induced
by over expression of adiponectin resemble those invoked by
AMP-DNM. The noted corrections in adiponectin in Lep
Ob after
AMP-DNM treatment may therefore significantly contribute to
the remarkable improvement in total body glucose homeostasis in
AMP-DNM treated mice. The effect of AMP-DNM points
towards improved expandability of adipose tissue of the mice.
In line with the restored adipose tissue function we observed
that AMP-DNM treatment reduces inflammation in EWAT as
well. Adipose tissue of obese individuals is rich in perilipin-
negative, predominantly dead, adipocytes surrounded by macro-
phages, giving rise to so-called crown-like structures [15,43].
AMP-DNM treatment of Lep
Ob mice was found to result in less
perilipin-negative adipocytes in EWAT, and concomitantly less
surrounding ATM. We observed reduced CLS formation
following treatment with APM-DNM and in line with this finding
macrophage-specific F4/80 RNA expression was reduced in
treated Lep
Ob mice to levels observed in lean controls. Important-
ly, also CD11c expression normalized and this marker is expressed
by the inflammatory macrophages, which are recruited to adipose
tissue and contribute to insulin resistance [24,44,47,48]. Evidence
presented here suggests improved adipogenesis. This in turn can also
contribute to reduced inflammation taking into account that
preadipocytes produce more inflammatory mediators compared to
mature adipocytes. More detailed analysis of EWAT revealed that
several genes whose expression is increased in Lep
Ob mice compared
to lean control mice, decreased following lowering of glycosphingo-
lipid content. The most prominently corrected genes were Ccl2 and
OPN. Importantly, both these proteins are considered to be essential
mediators in the recruitment of inflammatory macrophages towards
adipose tissue and to be involved in the induction of insulin resistance
[16,19]. OPN is specifically induced in ATM during high fat diet
induced obesity. Ablation of OPN does not interfere with obesity
itself, but reduces ATM content, inflammation and improves insulin
sensitivity of adipose tissue. In addition, it has been demonstrated that
OPN promotes Ccl2-mediated migration of macrophages to adipose
tissue [19]. Increased levels of OPN have also been reported in obese
human subjects. Interestingly, following weight loss after a dietary
intervention a significant down-regulation op OPN protein was
observed [49]. The reduced number of F4/80 positive macrophages
by AMP-DNM fits well with the finding that macrophage-derived
chemo-attractants Ccl2 and OPN are concomitantly reduced.
Interestingly, an anti-inflammatory effect of AMP-DNM has
previously been found in a hapten-induced model of colitis, which
possibly acts through macrophages. Amongst others reduced cellular
infiltration and myeloperoxidase activity were found in colon and
within lesions lower IFNc and IL-18 production was detected [50].
At a dose of 25 mg/kg/day AMP-DNM was found to have no
significant effect on food intake in Lep
Ob mice [33]. In the present
study a minor reduction in food intake was noted in the animals
treated with 100 mg/kg/day AMP-DNM. We therefore can not
rule out that on top of the beneficial effect of more marked
glycosphingolipid lowering, other factors add to this. It might be
that at the well tolerated higher dose of 100 mg/kg/day, AMP-
DNM also corrects appetite, energy expenditure, or brown
Table 3. Inflammatory mediators induced in Lep
Ob mice but
not reverted by AMP-DNM.
Lep
Ob versus lean control Lep
Ob AMP-DNM versus Lep
Ob
Symbol P value Fold up/down Symbol P value Fold down/up
Ccl8 0,000011 11,6 Ccl8 0,33 21,4
Il1r2 0,0066 4,1 Il1r2 0,16 21,5
Il13 0,00020 3,6 Il13 0,14 21,4
Ccl3 0,0026 2,9 Ccl3 0,95 21,0
Ccl4 0,0018 2,5 Ccl4 0,12 21,3
Cxcl10 0,0018 2,5 Cxcl10 0,86 1,1
Gusb 0,000001 2,4 Gusb 0,088 21,3
Itgb2 0,0010 2,4 Itgb2 0,95 1,0
Cxcl12 0,0051 2,0 Cxcl12 0,12 21,3
Ccl1 0,052 2,0 Ccl1 0,53 1,3
Tnf 0,0049 1,9 Tnf 0,37 1,1
Casp1 0,030 1,6 Casp1 0,85 21,0
Il6st 0,0032 21,6 Il6st 0,91 21,0
Ccl25 0,049 21,7 Ccl25 0,37 21,3
Hspcb 0,016 21,7 Hspcb 0,74 21,1
C3 0,00019 21,8 C3 0,85 1,0
Il16 0,0054 21,8 Il16 0,091 1,4
Il18 0,0017 22,0 Il18 0,79 1,1
Abcf1 0,000006 22,0 Abcf1 0,28 21,1
Gpr2 0,015 22,1 Gpr2 0,86 1,1
Ccr8 0,039 22,2 Ccr8 0,40 1,3
Data depicted are average up -or down regulated inflammatory genes when
Lep
Ob mice are compared to lean control mice (left three columns), which are
not changed by treatment with AMP-DNM (right three columns). Actual P
values are indicated.
doi:10.1371/journal.pone.0004723.t003
Table 4. Inflammatory mediators not induced in Lep
Ob but
induced by AMP-DNM.
Lep
Ob versus lean control Lep
Ob AMP-DNM versus Lep
Ob
Symbol P value Fold up/down Symbol P value Fold down/up
Ccr7 0,31 21,9 Ccr7 0,0028 2,8
Ccl11 0,46 21,1 Ccl11 0,017 1,8
Ccl22 0,65 21,2 Ccl22 0,0076 1,7
Cxcr3 0,91 1,0 Cxcr3 0,046 1,6
Data depicted are average values of unchanged inflammatory genes when
Lep
Ob mice are compared to lean control mice (left three columns), which are
induced by treatment with AMP-DNM (right three columns). Actual P values are
indicated.
doi:10.1371/journal.pone.0004723.t004
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Fig. 6 represents a model giving a possible explanation for our
observations regarding the effects of glycosphingolipid lowering by
AMP-DNM in adipose tissue of obese Lep
Ob mice. AMP-DNM
inhibits synthesis of glucosylceramide and subsequently GM3
formation, which results in restoration of insulin signalling. In
addition, adipogenesis and adiponectin production are improved,
all resulting in improved adipocyte function. As a consequence
inflammation is reduced because the trigger, a dysfunctional
adipocyte undergoing cell death with concomitant macrophage
activation, is lost. This fits our finding of reduced numbers of
crown-like structures and the reduction of the macrophage
chemoattractants Ccl2 and OPN. The noted improvement in
adipose tissue imposed by AMP-DNM treatment might add to the
overall corrections in tissues such as muscle and liver [33].
In conclusion, we demonstrate in Lep
Ob mice that AMP-DNM
exerts multiple beneficial effects on adipose tissue. Reduction of
glycosphingolipid content of adipocytes promotes their insulin
sensitivity directly and stimulates adipogenesis. As a consequence
ATM content of adipose tissue is reduced and this contributes to a
less deleterious environment.
Materials and Methods
Animals
C57BL/6J control mice and leptin-deficient obese (Lep
Ob) mice
(C57BL/6J background) were obtained from Harlan (Horst, the
Netherlands). Animals, n=5 per group unless stated differently,
were fed a commercial chow diet (AM-II) with or without 100 mg
AMP-DNM/kg bodyweight per day for four weeks (Arie Blok BV,
Woerden, the Netherlands). AMP-DNM has been synthesized as
described previously [33,51]. Studies were initiated using 7 week
old male mice. Approval for the study was obtained from the local
ethical committee for animal experiments.
Plasma and tissue sampling
Blood samples were collected by either tail vein or retro orbital
plexus puncture. After four weeks animals were sacrificed and
a large blood sample was collected by cardiac puncture.
Figure 6. Proposed mechanism of action of AMP-DNM. (A) Pathological GM3 levels inhibit insulin receptor signalling. Adipocyte dysfunction
and ultimately its death results in production of inflammatory mediators, reduction of adiponectin production and spillage of lipotoxic content,
which triggers macrophage activation and crown-like structure (CLS) formation. (B). Lowering of glycosphingolipids, especially GM3, restores insulin
signalling, improves adipogenesis, increases adiponectin and reduces lipotoxic spillage, all leading to less inflammation and disappearance of CLS.
doi:10.1371/journal.pone.0004723.g006
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directly, or immediately placed in liquid nitrogen or fixed in
formalin for further analysis.
Measurement of blood glucose, HbA1c, insulin and oral
glucose tolerance
Blood glucose levels were determined in plasma of non-fasted
animals using a Glucometer (Ascensia Elite, Bayer A.G.,
Leverkusen, Germany). HbA1c levels were measured in whole
blood of non- fasted animals using a single measurement A1C now
device (Metrika, Sunnyvale, USA). Fasted insulin levels were
determined by ELISA (Crystal Chem Inc, USA). Oral Glucose
Tolerance Tests (OGTT) were performed in fasted animals (4 h) by
gavage of glucose (500 mg glucose/kg body weight). Blood glucose
values were measured immediately before and 20, 40, 60, 90 and
120 min after glucose loading. Area under the curve (AUC)
(arbitrary units per minute) was determined for individual animals.
Analysis of lipids
Lipids were extracted according to Folch et al. [52]. Ceramide
and glucosylceramide were determined by high-performance
liquid chromatography (HPLC) analysis of orthophtaldehyde-
conjugated lipids according to a procedure previously described
[53]. Deacylation of lipids was performed in 0.5 ml 0.1 mol/l
NaOH in methanol in a microwave oven (CEM microwave
Solids/Moisture System SAM-155). Deacylated glycolipids were
derivatized on line for 30 min with O-phtaldehyde. Analysis was
performed using an HPLC system (Waters Associates, Milford,
USA) and a Hypersil BDS C18 3 m, 15064.6-mm reverse-phase
column (Alltech Inc., USA).
GM3 was detected by analysis of the acidic glycolipid fraction
obtained by Folch extraction as has been described previously with
slight modifications [54]. Gangliosides were desalted on a
disposable SPE C18 column (Bakerbond, Mallinckrodt Baker
Inc., Phillipsburg, NJ, USA) as described by Kundu [55] and
quantified following release of oligosaccharides from glycosphin-
golipids by ceramide glycanase (Recombinant endoglycocerami-
dase II, Takara Bio Inc., Otsu, Shiga, Japan) digestion. The
enzyme was used according to the manufacturer’s instructions.
Released oligosaccharides were labeled at their reducing end with
the fluorescent compound anthranilic acid (2-aminobenzoic acid),
prior to analysis using normal-phase high-performance liquid
chromatography [56]. Throughout the procedure trisialoganglio-
side-GT1b (Sigma, St Louis, Mo, USA) was used as an internal
standard.
Ex vivo analysis of insulin signalling in freshly isolated
adipocytes
Epididymal white adipose tissue (EWAT) of Lep
Ob mice and
AMP-DNM fed Lep
Ob mice was surgically removed and exposed
to collagenase treatment. Collagenase VIII (Sigma-Aldrich
Chemie BV, Zwijndrecht, The Netherlands) was diluted at
1 mg/ml in buffer (16HBSS, 20 mM Hepes (pH=7.4),
4.17 mM Sodiumbicarbonate and 2% fatty acid free BSA). Fat
tissue was cut into small pieces and incubated for 15 min at 37uC.
Next, adipocytes were enriched for by density centrifugation for
5 min at 2506g. Floating adipocytes were washed for three times.
Subsequently, adipocyte-enriched cell suspensions were stimulated
with or without insulin (100 nM, Sigma-Aldrich) for 10 min
followed by cell lysis in RIPA (150 mM NaCl, 10 mM Tris
pH 7.2, 0.1% SDS, 1% Triton, 1% deoxycholate, 5 mM EDTA)
buffer, supplemented with protease inhibitors (Roche, 1 tablet per
20 ml of lysis buffer). Equal amounts of total protein in lysates
were separated by SDS-PAGE, followed by standard ECL on
immunoblots using anti-pSer473 Akt, and anti-total Akt (Cell
Signaling Technology, Inc., USA) and goat anti-mouse peroxidase
(Biorad) [33].
Immunohistochemistry of adipose tissue macrophages
and adipocytes
EWAT was fixed in buffered formalin and embedded in
paraffin. Deparaffinized sections (4 mm) were stained with
haematoxylin-eosin. After quenching of endogenous peroxidase
activity by 0.3% H2O2 in methanol and blocking of free protein-
binding sites with 5% normal goat serum, sections were
immunostained for macrophages using rat IgG2b anti-mouse
F4/80 monoclonal antibody (AbD Serotec, Oxford, UK). In
some cases, doublestaining was performed for perilipin using a
monospecific guinea pig polyclonal antibody (Progen, Heidel-
berg, Germany). Specific secondary antibodies were peroxidase
(HRP)-conjugated goat anti-rat IgG (SouthernBiotech, Birming-
ham, AL) and biotinylated goat anti-guinea pig IgG (Chemicon,
Temecula, CA), respectively. The latter was followed by alkaline
phosphatase-conjugated streptavidin (DAKO, Glostrup, Den-
mark). Bound HRP activity was visualized using either
diaminobenzidine or NovaRed (Vector Laboratories, Burlin-
game, CA) as substrates; Vector Blue was used to detect AP
activity. Hematoxylin-and-eosin-stained 6-mm-thick sections of
EWAT and of omental adipose tissue (OAT) were analyzed
using a Leica DM5000B microscope with 106objective (Leica,
Rijswijk, The Netherlands) and Image Pro Plus 5.02 software
(Media Cybernetics, Bethesda, MD) to measure the cross-
sectional surface area of individual adipocytes as an indicator
of adipocyte cell size. To eliminate analysis of vessels and
interstitial cells a lower threshold of 1000 mm
2 was applied. Of
each mouse at least 150 adipocytes were measured in OAT and
in EWAT. Differences between average values of groups of mice
were statistically evaluated with the Kruskal Wallis rank sum
test and the Mann-Whitney U test. In addition, data are
presented as cumulative frequency distributions. Differences
were evaluated applying the 2-tailed Kolmogorov-Smirnov Z
test. Statistical analysis was performed using SPSS 16.0 (SPSS
Inc., Chicago, Il).
Crownlike structures (CLS) were identified in EWAT sections as
single adipocytes surrounded by at least 4 F4/80-positive
macrophages; CLS were counted in at least 25 mm
2 of EWAT
surface area.
RNA extraction and real time PCR
Total RNA was extracted from EWAT using TRIZOL
(Invitrogen, Breda, The Netherlands) and the nucleospin II
extraction kit (Macherey-Nagel GmbH, Duren, Germany). RNA
concentrations were measured using the Nanodrop Spectropho-
tometer (Nanodrop Technologies, USA). Equal amounts of RNA
were used to synthesize cDNA, according to the manufacturer’s
method (Invitrogen). cDNA was diluted 106 prior to gene-
specific analysis by real-time RT-PCR using an iCycler
MyiQTM system (Biorad Laboratories, Hercules, USA). Ex-
pression levels were normalized to ribosomal phosphoprotein
36B4. As primers were used: 36B4 forward primer ggacccgagaa-
gacctcctt, reverse primer gcacatcactcagaatttcaatgg; Pparc forward
primer ggaagaccactcgcattcctt, reverse primer tcgcactttggtattcttggag;
GLUT4 forward primer ctcatgggcctagccaatg, reverse primer
gggcgatttctcccacatac; Adipsin forward primer tccgcccctgaaccctacaa,
reverse primer taatggtgactaccccgtca; ACRP30/adiponectin forward
primer gctcctgctttggtccctccac, reverse primer gcccttcagctcctgtcattcc;
F4/80 forward primer ctttggctatgggcttccagtc, reverse primer
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tagcctttcttctgctg, reverse primer gcacactgtgtccgaactc. C/EBPa
forward primer ttacaacaggccaggtttcc, reverse primer ctctgggatggatc-
gattgt. aP2/FABP4 forward primer gcgtggaattcgatgaaatca, reverse
primer cccgccatctagggttatga. Pref1 forward primer agctggcggtcaa-
tatcatc, reverse primer agctctaaggaaccccggta. Data were analysed
using the delta Ct method [57]. Alternatively, RT
2 Profiler
TM PCR
arrays were used to monitor 84 mouse inflammatory cytokine and
receptor genes with build in house hold genes (Super Array
Bioscience Corporation, MD, USA). For cDNA synthesis the RT
2
PCRarrayfirststrandkitwasused accordingtotheinstructionofthe
manufacturer (Super Array Bioscience Corporation). In supplemen-
tary data table S1, the analyzed genes are listed.
ELISA
Ccl2/Mcp-1, osteopontin/OPN, and adiponectin/Acrp30 were
measured by ELISA according to the instructions of the
manufacturer (R&D systems, Inc., Minneapolis, USA). Adiponec-
tin was analysed in plasma samples of lean, Lep
Ob and AMP-DNM
treated Lep
Ob mice by westernblot, using goat anti-mouse
adiponectin antibody (R&D systems).
Statistical analysis
Values presented in figures represent means6S.E.M. Statistical
analysis of two groups was assessed by Student’s t-test (two tailed).
Level of significance is depicted in the figures with the actual P
values, p values,0.05 were considered significant.
Supporting Information
Table S1 Genes analyzed in relation to inflammation
Found at: doi:10.1371/journal.pone.0004723.s001 (0.13 MB
DOC)
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